Integrum AB Series B (INTEG-B) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.012x

Based on the latest financial reports, Integrum AB Series B (INTEG-B) has a cash flow conversion efficiency ratio of -0.012x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.16 Million ≈ $-232.34K USD) by net assets (Skr174.19 Million ≈ $18.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INTEG-B market cap overview for the company's overall valuation and market capitalisation.

Integrum AB Series B - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Integrum AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Integrum AB Series B Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Integrum AB Series B ranked by their cash flow conversion efficiency. Explore Integrum AB Series B earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Renovaro Biosciences Inc NASDAQ:RENB	0.085x
Tobii AB ST:TOBII	0.129x
Essen Tech Co. Ltd KQ:043340	-0.038x
N.D. Rubber Public Company Limited BK:NDR	0.014x
Ravinder Heights Limited NSE:RVHL	0.073x
Thai O.P.P. Public Company Limited BK:TOPP	0.030x
Kisan Telecom Co. Ltd KQ:035460	0.124x
Murray International Trust LSE:MYI	0.025x

Annual Cash Flow Conversion Efficiency for Integrum AB Series B (2014–2025)

The table below shows the annual cash flow conversion efficiency of Integrum AB Series B from 2014 to 2025. View INTEG-B stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr172.01 Million ≈ $18.51 Million	Skr-41.02 Million ≈ $-4.41 Million	-0.239x	-12.53%
2024-12-31	Skr177.88 Million ≈ $19.14 Million	Skr-37.70 Million ≈ $-4.06 Million	-0.212x	-137.47%
2023-12-31	Skr142.79 Million ≈ $15.37 Million	Skr-12.74 Million ≈ $-1.37 Million	-0.089x	+48.96%
2022-12-31	Skr143.53 Million ≈ $15.45 Million	Skr-25.10 Million ≈ $-2.70 Million	-0.175x	-37.73%
2021-12-31	Skr159.74 Million ≈ $17.19 Million	Skr-20.28 Million ≈ $-2.18 Million	-0.127x	+46.48%
2020-12-31	Skr24.29 Million ≈ $2.61 Million	Skr-5.76 Million ≈ $-620.14K	-0.237x	+69.94%
2019-12-31	Skr23.73 Million ≈ $2.55 Million	Skr-18.72 Million ≈ $-2.01 Million	-0.789x	+49.90%
2018-12-31	Skr16.05 Million ≈ $1.73 Million	Skr-25.28 Million ≈ $-2.72 Million	-1.575x	-62.44%
2017-12-31	Skr18.00 Million ≈ $1.94 Million	Skr-17.45 Million ≈ $-1.88 Million	-0.969x	-238.90%
2016-12-31	Skr10.53 Million ≈ $1.13 Million	Skr-3.01 Million ≈ $-324.30K	-0.286x	+88.15%
2015-12-31	Skr1.14 Million ≈ $122.14K	Skr-2.74 Million ≈ $-294.76K	-2.413x	-312.76%
2014-12-31	Skr1.13 Million ≈ $122.04K	Skr-663.00K ≈ $-71.35K	-0.585x	--

About Integrum AB Series B

ST:INTEG-B Sweden Medical Devices

Market Cap

$26.19 Million

Skr243.36 Million SEK

Market Cap Rank

#24318 Global

#466 in Sweden

Share Price

Skr9.35

Change (1 day)

+0.32%

52-Week Range

Skr6.96 - Skr15.64

All Time High

Skr102.00